Helmer Scientific, Noblesville, Ind, has recently acquired the ThermoLine Product Lines from ThermoGenesis Corp, as part of Helmer’s growth strategy and a continuing commitment to providing high-quality products to the medical and blood bank community.
The acquisition is an enhancement of the Helmer core biological sample processing product lines.
“This line acquisition is focused on providing a solution to our customers who have voiced a need for a reliable rapid plasma freezing system,” says Bruce King, president, Helmer Scientific. “Helmer Scientifics’ long-standing service orientation and commitment to worldwide customer relationships, combined with our technical expertise in blood storage and processing equipment, uniquely position Helmer to support ThermoGenesis’ longtime customers with a service and support infrastructure for both their freezing and thawing devices.”
ThermoGenesis is among the leading suppliers of enabling technologies for the processing, storage, and administration of cell therapies. “As was the case with our divestiture of the CryoSeal product line in mid-2012, this transaction is part of our long-term strategy to focus on our core business of developing enabling technologies for the stem cell regernerative medicine market,” says Matthew Plavan, CEO, ThermoGenesis.
[Source: Helmer Scientific]
